Insilico Medicine, an AI-technology drug discovery firm, has raised $37 million in its Series B funding while risk management platform IceKredit secures $47 million in pre-Series C round.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in